Carrus Capital Corporation Receives Shareholder Approval to Plan of Arrangement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES


Plan of Arrangement

Carrus Capital Corporation (TSX VENTURE:CHQ) ("Carrus") today announced that it
has received shareholder approval to the previously announced plan of
arrangement (the "Arrangement") pursuant to which Carrus will transfer its
pharmaceutical portfolio, largely consisting of but not limited to chemical
assets, related technologies and associated intellectual property and patents
for: certain cationic peptide molecules for the prevention of catheter-related
infections and certain dermatological diseases; certain lipopeptide molecules
for the treatment of serious Gram-positive bacterial infections intravenous; and
dinucleotide molecules for the treatment of hepatitis-related infections, to its
three wholly owned subsidiaries BioAB Strategies Ltd. ("BioAB"), BioDE Ventures
Ltd. ("BioDE"), and BioHEP Technologies Ltd. ("BioHEP"), respectively, in
exchange for the three subsidiaries issuing shares to the shareholders of
Carrus. More specific information and definitions for the transferred portfolio
can be found under Carrus' profile on the System for Electronic Document
Analysis and Retrieval at www.sedar.com.


Under the terms of the Arrangement, shareholders of Carrus are entitled to
receive one share of each of BioAB, BioDE, and BioHEP for every Carrus share
held as of the share distribution record date, multiplied by the conversion
factor (as that term is defined in the Carrus information circular dated as of
February 12, 2014). As of March 13, 2014, all of Carrus' option holders are
entitled to receive shares of each of BioAB, BioDE, and BioHEP upon the exercise
of their Carrus options prior to the share distribution record date. At the
present time, the directors of Carrus contemplate setting a share distribution
record date in April 2014.


After the spinoff, Carrus will focus on investment activities in enterprises
located in Canada and the United States, although investments may extend
globally (including the purchase of securities listed on foreign stock
exchanges).


As separate companies, BioAB, BioDE, and BioHEP will have direct access to
public and private capital markets and will also evaluate and may acquire
additional licensing opportunities from time to time.


Carrus, BioAB, BioDE, and BioHEP will now independently be able to establish
their compensation programs in order to better attract, motivate and retain its
directors, officers and employees, thereby better aligning their management and
employee incentives with their respective companies' objectives and the
interests of shareholders.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this news release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Carrus Capital Corporation
Bruce Schmidt
Chief Executive Officer and Corporate Secretary
604-760-0160